Evidence for Keltican Use in Older Adults and Stroke Patients
Based on available evidence, Keltican (uridine monophosphate + folic acid + vitamin B12) shows clinical benefit for peripheral neuropathy in older adults, but there is no direct evidence supporting its use specifically in stroke patients.
Evidence in Older Adults with Peripheral Neuropathy
The research evidence demonstrates that Keltican is effective for treating peripheral neuropathy in older populations, though this is based on observational studies rather than high-quality randomized trials:
Clinical Efficacy Data
Pain reduction is substantial and consistent across multiple studies. In a large observational study of 212 patients with peripheral neuropathy, the painDETECT questionnaire global score decreased from 17.5 to 8.8 points after 2 months of treatment (p<0.001) 1. A similar study of 48 patients showed pain scores dropping from 17.3 ± 5.9 to 10.3 ± 6.1 (p<0.001) 2. These represent clinically meaningful reductions in neuropathic pain intensity.
Functional improvements extend beyond pain relief. In patients with compressive neuralgias, the combination of nucleotides plus vitamin B12 demonstrated statistically significant superiority over vitamin B12 alone in a randomized, double-blind trial of 400 patients 3. Concomitant analgesic and anti-inflammatory medications were reduced or discontinued in 77.4% of patients 2, 1.
Mechanistic Support from Guidelines
The ESPEN guidelines provide indirect support for the B-vitamin components of Keltican. For Parkinson's disease patients (who share similar age demographics with many neuropathy patients), ESPEN recommends regular monitoring and supplementation of vitamin D, folic acid, and vitamin B12 4. The ESPEN micronutrient guideline specifically addresses folic acid supplementation, recommending 1-5 mg daily for dietary deficiency 5.
Objective Neurological Improvements
Beyond subjective pain scores, one small study in diabetic polyneuropathy patients showed significant improvement in sensory conduction velocity of the sural nerve after 3 months of treatment 6. More recent systematic review data indicates that folate supplementation can increase epidermal nerve fiber density by up to 97%, representing actual structural nerve regeneration 7.
Evidence in Stroke Patients
There is no direct clinical evidence for Keltican use specifically in stroke patients. The provided evidence does not include any studies examining this combination in stroke populations. This represents a critical gap.
Indirect Considerations
The mechanistic rationale exists through folate-mediated one-carbon metabolism, which is implicated in neurological health 8. Folate supplementation has been shown to reduce homocysteine and high-sensitivity C-reactive protein levels 7, both relevant to vascular health. However, mechanistic plausibility should not be equated with clinical efficacy in the absence of stroke-specific trials.
Safety Profile
The safety profile is excellent across all studied populations. Among 1,367 individuals across multiple studies, only one adverse event was reported 7. The ESPEN guideline notes that oral folic acid administration in recommended dosages is considered non-toxic, with excess excreted in urine 5.
Important Caveat
When supplementing with folic acid, always evaluate and treat concomitant vitamin B12 deficiency. The ESPEN guideline explicitly warns that if B12 deficiency is present and ignored during folic acid supplementation, the blood picture may improve but neurological manifestations may worsen 5. This is particularly relevant in older adults who have higher rates of B12 malabsorption.
Clinical Recommendations
For Older Adults with Peripheral Neuropathy:
- Consider Keltican as an adjunctive treatment for symptomatic peripheral neuropathy, particularly when pain is a prominent feature
- Expect pain reduction of 3-9 points on standard scales within 2 months
- Monitor for potential reduction in analgesic requirements
- Screen for B12 deficiency before initiating treatment (measure serum B12 and methylmalonic acid if B12 is borderline)
- Treatment duration of at least 2-3 months appears necessary for optimal benefit
For Stroke Patients:
- Cannot recommend Keltican specifically for stroke based on current evidence
- If peripheral neuropathy develops post-stroke (which can occur), the evidence for neuropathy treatment would apply
- Focus instead on guideline-directed stroke prevention and rehabilitation strategies
Quality of Evidence Limitations:
The evidence for Keltican consists primarily of open-label observational studies and one randomized trial comparing it to B12 alone 3. While results are consistent and clinically meaningful, higher-quality placebo-controlled trials with longer follow-up are needed to establish definitive efficacy, particularly in specific populations like stroke survivors.